KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Emergent BioSolutions (EBS) Amortization - Deferred Charges (2016 - 2017)

Historic Amortization - Deferred Charges for Emergent BioSolutions (EBS) over the last 3 years, with Q4 2017 value amounting to $95000.0.

  • Emergent BioSolutions' Amortization - Deferred Charges fell 5518.87% to $95000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $680000.0, marking a year-over-year increase of 1147.54%. This contributed to the annual value of $681000.0 for FY2017, which is 1280.41% down from last year.
  • According to the latest figures from Q4 2017, Emergent BioSolutions' Amortization - Deferred Charges is $95000.0, which was down 5518.87% from $195000.0 recorded in Q3 2017.
  • In the past 5 years, Emergent BioSolutions' Amortization - Deferred Charges ranged from a high of $215000.0 in Q3 2015 and a low of $95000.0 during Q4 2017
  • Moreover, its 3-year median value for Amortization - Deferred Charges was $195000.0 (2017), whereas its average is $189111.1.
  • As far as peak fluctuations go, Emergent BioSolutions' Amortization - Deferred Charges skyrocketed by 761.42% in 2016, and later plummeted by 5518.87% in 2017.
  • Emergent BioSolutions' Amortization - Deferred Charges (Quarter) stood at $197000.0 in 2015, then increased by 7.61% to $212000.0 in 2016, then tumbled by 55.19% to $95000.0 in 2017.
  • Its last three reported values are $95000.0 in Q4 2017, $195000.0 for Q3 2017, and $195000.0 during Q2 2017.